What is the global market size of Duchenne Muscular Dystrophy Market?

Duchenne Muscular Dystrophy Market size was valued at USD 1301.44 million in 2019 and is poised to grow from USD 1362.61 million in 2023 to USD 2060.11 million by 2031, growing at a CAGR of 4.7% in the forecast period (2024-2031).

Duchenne Muscular Dystrophy Market Size

Duchenne Muscular Dystrophy Market Insights

Global Duchenne Muscular Dystrophy Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.34 billion in 2024 to USD 5.64 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

Duchenne muscular dystrophy is an illness in which muscular weakness happens. Muscle weakness is a defining feature of this hereditary condition. This rare illness primarily affects males. This illness results in mental retardation, respiratory failure, pneumonia, heart failure, muscle weakness, and intellectual incapacity. With the help of this diagnostic care, people with Duchenne muscular dystrophy can receive precise and effective treatment. This sort of diagnostic therapy lessens or manages symptoms but does not provide a cure. In addition to stem cell therapy and gene therapy, medications like steroids are used to treat Duchenne muscular dystrophy and lessen its symptoms.

In the case of DMD, a characteristic of this inherited illness is muscle weakness. Males are the main victims of this rare disease. Mental retardation, pneumonia, heart failure, respiratory failure, muscle weakness, and intellectual disability are all side effects of this condition. People with Duchenne muscular dystrophy can get precise and efficient treatment with the use of this diagnostic care. While not offering a cure, this type of diagnostic therapy lowers or manages symptoms. Drugs like steroids are used to treat Duchenne muscular dystrophy and decrease its symptoms in addition to stem cell therapy and gene therapy.

Global duchenne muscular dystrophy market is anticipated to rise as R&D spending increases to create possible treatments for DMD. For instance, the Muscular Dystrophy Association (MDA), United States, funded $75,000 in research and development to create a DMD treatment. More than 150 hospitals, healthcare facilities, and care facilities in the United States and other nations have received grants from the group.

Additionally, factors like ongoing research into gene and stem cell therapy and exon skipping drugs for DMD treatment are projected to drive global duchenne muscular dystrophy market.

US Duchenne Muscular Dystrophy Market is poised to grow at a sustainable CAGR for the next forecast year.

FAQs

Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Pfizer Inc. (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Mylan N.V. (US) ', 'Fresenius Kabi AG (Germany) ', 'Hikma Pharmaceuticals plc (UK) ', 'Novartis AG (Switzerland) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Bristol Myers Squibb Company (US) ', 'GSK plc (UK) ', 'Bayer AG (Germany) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Boehringer Ingelheim (Germany) ', 'Sanofi (France) ', 'Sarepta Therapeutics, Inc. (US) ', 'Aurobindo Pharma (India) ', 'Capricor Therapeutics, Inc. (US) ', 'Catalyst Pharmaceuticals Inc (US) ', 'EspeRare Foundation (Switzerland) ', 'FibroGen, Inc. (US) ', 'Italfarmaco S.p.A (Italy)'

Prevalence of duchenne muscular dystrophy is on the rise, and factors that are driving its market growth include increased awareness campaigns about the disorder, the development of mutation-specific therapies, the rise in product pipelines, the introduction of therapies like Exondys51 and Translarna, and the use of corticosteroid-based anti-inflammatory drugs.

The introduction of novel pharmaceuticals and treatments, disease-modifying treatments, significant backing from numerous firms for drug research, and support from patient advocacy groups on the regulatory approval process are the main factors driving the global market for duchenne muscular dystrophy.

North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.